Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models

In this study, chTNT-3/CpG retained immunostimulatory activity of the CpG moiety and enabled delivery to tumors. Because systemically administered CpG rapidly clear the body and do not accumulate into tumors, chTNT-3/CpG provide a solution to the limitations observed in preclinical and clinical trials.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research